Winning its second FDA approval this year, Boehringer Ingelheim's oral drug Jascayd is now cleared for use in the U.S. by ...

Columnist Samuel Kirton talks with the Pulmonary Fibrosis Foundation's Amy Hajari Case, MD, about the Accelerate Research ...

GRI-0621, an experimental oral therapy from GRI Bio, boosts lung function in adults with IPF, according to top-line clinical ...

Caring for someone you love is intimate, humbling, and grounding, writes columnist Ann Reynoso, who swapped caregiver roles with her husband.

Columnist Sam Kirton has wonderful memories of holiday presents, but the greatest gift he's received came in the form of a lung transplant.

In her columns debut, Kylene Henderson shares how her family learned to work together after her husband's pulmonary fibrosis diagnosis.

Building on positive Phase 2 data, Puretech plans to launch a Phase 3 trial to further evaluate its experimental IPF therapy deupirfenidone.

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Birchbiomed’s FS2 (kynurenic acid) for the treatment of idiopathic pulmonary fibrosis (IPF). Orphan drug status is ...

A novel inhalable therapy has shown promise for treating idiopathic pulmonary fibrosis (IPF) by outperforming an approved oral medicine in a mouse study. The new treatment, called VB-RT NPs, consists ...